KR101743783B1 - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number
KR101743783B1
KR101743783B1 KR1020117012975A KR20117012975A KR101743783B1 KR 101743783 B1 KR101743783 B1 KR 101743783B1 KR 1020117012975 A KR1020117012975 A KR 1020117012975A KR 20117012975 A KR20117012975 A KR 20117012975A KR 101743783 B1 KR101743783 B1 KR 101743783B1
Authority
KR
South Korea
Prior art keywords
compound
formula
delete delete
purine
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117012975A
Other languages
English (en)
Korean (ko)
Other versions
KR20110097816A (ko
Inventor
홀리 에스켄
베스 아담스 노튼
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20110097816A publication Critical patent/KR20110097816A/ko
Application granted granted Critical
Publication of KR101743783B1 publication Critical patent/KR101743783B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117012975A 2008-12-08 2009-12-07 신규 화합물 Expired - Fee Related KR101743783B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
US61/120,596 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds

Publications (2)

Publication Number Publication Date
KR20110097816A KR20110097816A (ko) 2011-08-31
KR101743783B1 true KR101743783B1 (ko) 2017-06-05

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117012975A Expired - Fee Related KR101743783B1 (ko) 2008-12-08 2009-12-07 신규 화합물

Country Status (22)

Country Link
US (3) US9163024B2 (enExample)
EP (1) EP2370440B1 (enExample)
JP (1) JP5666464B2 (enExample)
KR (1) KR101743783B1 (enExample)
CN (1) CN102245606B (enExample)
AU (1) AU2009324811B2 (enExample)
BR (1) BRPI0922134A2 (enExample)
CA (1) CA2746316C (enExample)
CY (1) CY1116032T1 (enExample)
DK (1) DK2370440T3 (enExample)
EA (1) EA020037B1 (enExample)
ES (1) ES2527354T3 (enExample)
HR (1) HRP20150026T1 (enExample)
IL (1) IL213032A (enExample)
MX (1) MX2011006022A (enExample)
PL (1) PL2370440T3 (enExample)
PT (1) PT2370440E (enExample)
RS (1) RS53777B1 (enExample)
SI (1) SI2370440T1 (enExample)
SM (1) SMT201500012B (enExample)
WO (1) WO2010068581A1 (enExample)
ZA (1) ZA201103397B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
CN104202977A (zh) * 2012-03-22 2014-12-10 转化技术制药有限责任公司 小分子glp1r激动剂的三(羟甲基)氨基甲烷盐及其药物组合物和用途
CN121219290A (zh) 2023-02-27 2025-12-26 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
JP2003534238A (ja) * 1999-12-15 2003-11-18 スミスクライン・ビーチャム・コーポレイション シス−４−シアノ−４−［３−（シクロペンチルオキシ）−４−メトキシフェニル］シクロヘキサン−１−カルボン酸の塩。
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity

Also Published As

Publication number Publication date
PT2370440E (pt) 2015-01-14
ZA201103397B (en) 2012-01-25
EA020037B1 (ru) 2014-08-29
BRPI0922134A2 (pt) 2015-08-18
CY1116032T1 (el) 2017-01-25
EP2370440A4 (en) 2012-05-30
IL213032A (en) 2015-02-26
JP2012511028A (ja) 2012-05-17
MX2011006022A (es) 2011-06-28
EP2370440B1 (en) 2014-11-12
PL2370440T3 (pl) 2015-05-29
RS53777B1 (sr) 2015-06-30
ES2527354T3 (es) 2015-01-22
SMT201500012B (it) 2015-05-03
US20150366870A1 (en) 2015-12-24
AU2009324811A1 (en) 2011-06-23
CN102245606B (zh) 2014-08-20
IL213032A0 (en) 2011-07-31
CA2746316A1 (en) 2010-06-17
EA201170783A1 (ru) 2011-12-30
CN102245606A (zh) 2011-11-16
DK2370440T3 (en) 2014-12-08
US9163024B2 (en) 2015-10-20
EP2370440A1 (en) 2011-10-05
CA2746316C (en) 2017-01-03
HRP20150026T1 (hr) 2015-02-13
KR20110097816A (ko) 2011-08-31
US20110251218A1 (en) 2011-10-13
US20170027945A1 (en) 2017-02-02
AU2009324811B2 (en) 2013-01-24
WO2010068581A1 (en) 2010-06-17
SI2370440T1 (sl) 2015-02-27
JP5666464B2 (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
CN1432018A (zh) 三唑并[4,5－d]嘧啶化合物的新晶形和非晶形
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
KR101743783B1 (ko) 신규 화합물
KR20110002090A (ko) 오르베피탄트 말레에이트의 무수 결정 형태
KR20150046369A (ko) 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
US7829711B2 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
JP3215850B2 (ja) ハロアルコキシ基を含有するピロロ［３，２―ｃ］キノリン誘導体及び薬学的に許容されるその塩
US8273753B2 (en) Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
CN121039113A (zh) 维格列净与所选共晶形成剂的结晶复合物、其制备方法及其在制备药物中的用途
JPH0211592A (ja) 光学活性なジヒドロピリジンホスホン酸エステル
US20250179037A1 (en) Crystalline form of leucogen and method for preparation thereof and use thereof
CN117843633A (zh) 亚砜亚胺类化合物、其药物组合物和用途
CN113493435A (zh) 一种化合物a苯甲酸盐的无定形及其制备方法和含有该无定形的药物组合物
US7153961B2 (en) Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
EP1918289A2 (en) Crystalline fluoroquinolone arginine salt form
JPH11240882A (ja) 縮合ピリダジン誘導体、その製造法および用途
JPH03163079A (ja) キサンチン誘導体、それらを有効成分とする気管支拡張剤及び脳機能改善剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200531

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200531